NYSE
210.58USD
+1.60 (+0.77%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
13.5B
P/E
—
EPS
—
Beta
0.91
52W range
101-213.44
Day range
207.88–213.44
Open
207.89
Prev close
208.98
Volume
422K
Avg volume
840.8K
Dividend
0.00
IPO
1995-10-31
https://www.zacks.com/commentary/2936949/best-growth-stocks-to-buy-for-june-15th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions|growth_additions-2936949 · 6/15/2026+0.80
https://www.zacks.com/commentary/2935571/best-growth-stocks-to-buy-for-june-11th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions|growth_additions-2935571 · 6/11/2026+1.00
https://www.zacks.com/stock/news/2932675/davita-expands-comprehensive-kidney-care-through-dialysis-services?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2932675 · 6/4/2026+0.60
https://www.zacks.com/commentary/2932001/best-growth-stocks-to-buy-for-june-4th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions|growth_additions-2932001 · 6/4/2026+1.00
https://www.zacks.com/stock/news/2928934/gs-expects-record-global-m-a-in-2026-will-this-boost-its-ib-business?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2928934 · 5/29/2026
https://www.zacks.com/stock/news/2928806/what-makes-cf-industries-stock-a-solid-investment-option-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2928806 · 5/29/2026+0.10
https://www.zacks.com/stock/news/2924402/nordson-ndsn-tops-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2924402 · 5/20/2026+0.00
https://www.zacks.com/commentary/2923051/best-value-stocks-to-buy-for-may-19th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions|value_additions-2923051 · 5/19/2026+1.00
https://www.zacks.com/stock/news/2919390/analog-devices-adi-outperforms-broader-market-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v2-2919390 · 5/11/2026+0.10
https://www.zacks.com/commentary/2919295/3-highly-ranked-medical-stocks-to-buy-now-dva-gmed-pgny?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2919295 · 5/11/2026+1.00
https://www.cnbc.com/2026/05/09/greg-abel-knows-berkshire-cold-but-some-miss-the-buffett-magic.html · 5/9/2026+0.80
https://www.fool.com/investing/2026/04/07/youll-never-guess-which-healthcare-stock-delivered/ · 4/7/2026+0.50
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works